Despite repeated assurances from rival camps that toxic loads of amyloid beta and tau are likely causes of Alzheimer's disease, no one is quite sure what is going on and clinical failures are routine. But investigators at UC San Diego School of Medicine say they have been garnering some preclinical clues that would suggest there could be a new pathway to follow in the clinic.
Working with the knowledge that the CD44v6 protein acts as a co-receptor for receptor tyrosine kinases like MET and VEGFR-2 that drive pancreatic cancer, a group of German investigators at the Karlsruher Institut fur Technologie (KIT) say they've successfully tested a new peptide approach in mice that throws up a hurdle that can blunt and perhaps even stop the development of the disease. Read more >>
After sequencing the DNA of patients suffering from severe diarrhea and their healthy relatives, researchers at Michigan State say they have identified a new microbiome strategy for aiding patients by better balancing levels of healthy and sickening gut bacteria. Read more >>
POPULAR COMMENT THREADS
A group of RNA experts say they've developed a potential upgrade for the wildly popular CRISPR/Cas9 gene editing tech that has been picked up in labs around the world.
A team led by Janet Rubin at the University of North Carolina School of Medicine recently found a novel method to push stem cells into forming bone.
Researchers at Baylor College of Medicine have published animal research that provides some proof that an experimental drug could one day provide a new therapeutic to effectively fight fat by pushing "bad" white fat to become "good" brown fat.
Actually eradicating the virus that causes AIDS has been thwarted by the virus' ability to hide out in dormant cells. Now researchers say that a generic alcoholism drug called disulfiram has demonstrated the ability to wake up the virus and flush it out for destruction.
Studying the bone microenvironment may offer new insights into better drugs for fighting prostate cancer metastasis.
Cambridge, MA-based Warp Drive Bio is launching a new cancer drug platform which the biotech claims will open up new, previously undruggable targets to developers.
From Our Sister Sites
While working to catch up with other vaccine developers in the race for a respiratory syncytial virus (RSV) vaccine, San Francisco-based Vaxart this week unveiled data demonstrating its candidate's ability to create a "substantial" immune response in a preclinical challenge model.
An FDA warning letter found that for years, Dr. Reddy's Laboratories was testing drug batches in a laboratory that the FDA was never told existed and often shipped to the U.S. products that had repeatedly failed tests for impurities.